Impact of neoadjuvant FLOT treatment of advanced gastric and gastroesophageal junction cancer following surgical therapy
IntroductionTherapeutic treatment for advanced-stage (T2–T4) gastroesophageal junction (GEJ) and gastric cancer involves neoadjuvant chemotherapy with subsequent surgical intervention.MethodNeoadjuvant oncological treatment for GEJ and gastric cancer previously consisted of the intravenous administr...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-04-01
|
| Series: | Frontiers in Surgery |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fsurg.2023.1148984/full |
| _version_ | 1797854040290230272 |
|---|---|
| author | Attila Paszt Zsolt Simonka Krisztina Budai Zoltan Horvath Marton Erdos Marton Vas Aurel Ottlakan Tibor Nyari Zoltan Szepes Gabriella Uhercsak Aniko Maraz Laszlo Torday Laszlo Tiszlavicz Judit Olah Gyorgy Lazar |
| author_facet | Attila Paszt Zsolt Simonka Krisztina Budai Zoltan Horvath Marton Erdos Marton Vas Aurel Ottlakan Tibor Nyari Zoltan Szepes Gabriella Uhercsak Aniko Maraz Laszlo Torday Laszlo Tiszlavicz Judit Olah Gyorgy Lazar |
| author_sort | Attila Paszt |
| collection | DOAJ |
| description | IntroductionTherapeutic treatment for advanced-stage (T2–T4) gastroesophageal junction (GEJ) and gastric cancer involves neoadjuvant chemotherapy with subsequent surgical intervention.MethodNeoadjuvant oncological treatment for GEJ and gastric cancer previously consisted of the intravenous administration of epirubicin, cisplatin and fluorouracil (ECF) or epirubicin, cisplatin and capecitabine (ECX) combination (Group 1). The new protocol (FLOT, F: 5-FU, L: leucovorin, O: oxaliplatin, T: docetaxel), included patients with resectable GEJ and gastric cancer who had a clinical stage cT2 or higher nodal positive cN+ disease (Group 2). Between 31 December 2008 and 31 October 2022, the effect of different oncological protocols in terms of surgical outcomes in cases of T2–T4 tumours were retrospectively evaluated. Results of randomly assigned patients from the earlier ECF/ECX protocol (n = 36) (Group 1) and the new FLOT protocol (n = 52) (Group 2) were compared. Effect of different neoadjuvant therapies on tumour regression, types of possible side effects, type of surgery, and oncological radicality of surgical procedures were analysed.ResultsWhen comparing the two groups, we found that in case of the FLOT neoadjuvant chemotherapy (Group 2, n = 52), complete regression was achieved in 13.95% of patients, whereas in the case of ECF/ECX (Group 1, n = 36), complete regression occurred in only 9.10% of patients. Furthermore, in the FLOT group, the mean number of lymph nodes removed was slightly higher (24.69 vs. 20.13 in the ECF/ECX group). In terms of the safety resection margin (proximal), no significant difference was found between the two treatment groups. Nausea and vomiting were the most common side effects. The occurrence of diarrhea was significantly higher in the FLOT group (p = 0.006). Leukopenia and nausea occurred more commonly with the old protocol (Group 1). The rate of neutropenia was lower following FLOT treatment (p = 0.294), with the lack of grade II and III cases. Anaemia occured at a significantly higher rate (p = 0.036) after the ECF/ECX protocol.ConclusionsAs a result of the FLOT neoadjuvant oncological protocol for advanced gastro-esophageal junction and gastric cancer, the rate of complete tumour regression increased significantly. The rate of side effects was also appreciably lower following the FLOT protocol. These results strongly suggest a significant advantage of the FLOT neoadjuvant treatment used before surgery. |
| first_indexed | 2024-04-09T20:00:39Z |
| format | Article |
| id | doaj.art-3a74c0c67f4b470b8a89f7f85107b42c |
| institution | Directory Open Access Journal |
| issn | 2296-875X |
| language | English |
| last_indexed | 2024-04-09T20:00:39Z |
| publishDate | 2023-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Surgery |
| spelling | doaj.art-3a74c0c67f4b470b8a89f7f85107b42c2023-04-03T05:01:39ZengFrontiers Media S.A.Frontiers in Surgery2296-875X2023-04-011010.3389/fsurg.2023.11489841148984Impact of neoadjuvant FLOT treatment of advanced gastric and gastroesophageal junction cancer following surgical therapyAttila Paszt0Zsolt Simonka1Krisztina Budai2Zoltan Horvath3Marton Erdos4Marton Vas5Aurel Ottlakan6Tibor Nyari7Zoltan Szepes8Gabriella Uhercsak9Aniko Maraz10Laszlo Torday11Laszlo Tiszlavicz12Judit Olah13Gyorgy Lazar14Department of Surgery, University of Szeged, Szeged, HungaryDepartment of Surgery, University of Szeged, Szeged, HungaryDepartment of Surgery, University of Szeged, Szeged, HungaryDepartment of Surgery, University of Szeged, Szeged, HungaryDepartment of Surgery, University of Szeged, Szeged, HungaryDepartment of Surgery, University of Szeged, Szeged, HungaryDepartment of Surgery, University of Szeged, Szeged, HungaryDepartment of Medical Physics and Informatics, University of Szeged, Szeged, Hungary1st Department of Internal Medicine, University of Szeged, Szeged, HungaryDepartment of Oncotherapy, University of Szeged, Szeged, HungaryDepartment of Oncotherapy, University of Szeged, Szeged, HungaryDepartment of Oncotherapy, University of Szeged, Szeged, HungaryDepartment of Pathology, University of Szeged, Szeged, HungaryDepartment of Oncotherapy, University of Szeged, Szeged, HungaryDepartment of Surgery, University of Szeged, Szeged, HungaryIntroductionTherapeutic treatment for advanced-stage (T2–T4) gastroesophageal junction (GEJ) and gastric cancer involves neoadjuvant chemotherapy with subsequent surgical intervention.MethodNeoadjuvant oncological treatment for GEJ and gastric cancer previously consisted of the intravenous administration of epirubicin, cisplatin and fluorouracil (ECF) or epirubicin, cisplatin and capecitabine (ECX) combination (Group 1). The new protocol (FLOT, F: 5-FU, L: leucovorin, O: oxaliplatin, T: docetaxel), included patients with resectable GEJ and gastric cancer who had a clinical stage cT2 or higher nodal positive cN+ disease (Group 2). Between 31 December 2008 and 31 October 2022, the effect of different oncological protocols in terms of surgical outcomes in cases of T2–T4 tumours were retrospectively evaluated. Results of randomly assigned patients from the earlier ECF/ECX protocol (n = 36) (Group 1) and the new FLOT protocol (n = 52) (Group 2) were compared. Effect of different neoadjuvant therapies on tumour regression, types of possible side effects, type of surgery, and oncological radicality of surgical procedures were analysed.ResultsWhen comparing the two groups, we found that in case of the FLOT neoadjuvant chemotherapy (Group 2, n = 52), complete regression was achieved in 13.95% of patients, whereas in the case of ECF/ECX (Group 1, n = 36), complete regression occurred in only 9.10% of patients. Furthermore, in the FLOT group, the mean number of lymph nodes removed was slightly higher (24.69 vs. 20.13 in the ECF/ECX group). In terms of the safety resection margin (proximal), no significant difference was found between the two treatment groups. Nausea and vomiting were the most common side effects. The occurrence of diarrhea was significantly higher in the FLOT group (p = 0.006). Leukopenia and nausea occurred more commonly with the old protocol (Group 1). The rate of neutropenia was lower following FLOT treatment (p = 0.294), with the lack of grade II and III cases. Anaemia occured at a significantly higher rate (p = 0.036) after the ECF/ECX protocol.ConclusionsAs a result of the FLOT neoadjuvant oncological protocol for advanced gastro-esophageal junction and gastric cancer, the rate of complete tumour regression increased significantly. The rate of side effects was also appreciably lower following the FLOT protocol. These results strongly suggest a significant advantage of the FLOT neoadjuvant treatment used before surgery.https://www.frontiersin.org/articles/10.3389/fsurg.2023.1148984/fullFLOT therapyneoadjuvant treatmentadvanced gastric tumourgastroesophageal junctionsurgery |
| spellingShingle | Attila Paszt Zsolt Simonka Krisztina Budai Zoltan Horvath Marton Erdos Marton Vas Aurel Ottlakan Tibor Nyari Zoltan Szepes Gabriella Uhercsak Aniko Maraz Laszlo Torday Laszlo Tiszlavicz Judit Olah Gyorgy Lazar Impact of neoadjuvant FLOT treatment of advanced gastric and gastroesophageal junction cancer following surgical therapy Frontiers in Surgery FLOT therapy neoadjuvant treatment advanced gastric tumour gastroesophageal junction surgery |
| title | Impact of neoadjuvant FLOT treatment of advanced gastric and gastroesophageal junction cancer following surgical therapy |
| title_full | Impact of neoadjuvant FLOT treatment of advanced gastric and gastroesophageal junction cancer following surgical therapy |
| title_fullStr | Impact of neoadjuvant FLOT treatment of advanced gastric and gastroesophageal junction cancer following surgical therapy |
| title_full_unstemmed | Impact of neoadjuvant FLOT treatment of advanced gastric and gastroesophageal junction cancer following surgical therapy |
| title_short | Impact of neoadjuvant FLOT treatment of advanced gastric and gastroesophageal junction cancer following surgical therapy |
| title_sort | impact of neoadjuvant flot treatment of advanced gastric and gastroesophageal junction cancer following surgical therapy |
| topic | FLOT therapy neoadjuvant treatment advanced gastric tumour gastroesophageal junction surgery |
| url | https://www.frontiersin.org/articles/10.3389/fsurg.2023.1148984/full |
| work_keys_str_mv | AT attilapaszt impactofneoadjuvantflottreatmentofadvancedgastricandgastroesophagealjunctioncancerfollowingsurgicaltherapy AT zsoltsimonka impactofneoadjuvantflottreatmentofadvancedgastricandgastroesophagealjunctioncancerfollowingsurgicaltherapy AT krisztinabudai impactofneoadjuvantflottreatmentofadvancedgastricandgastroesophagealjunctioncancerfollowingsurgicaltherapy AT zoltanhorvath impactofneoadjuvantflottreatmentofadvancedgastricandgastroesophagealjunctioncancerfollowingsurgicaltherapy AT martonerdos impactofneoadjuvantflottreatmentofadvancedgastricandgastroesophagealjunctioncancerfollowingsurgicaltherapy AT martonvas impactofneoadjuvantflottreatmentofadvancedgastricandgastroesophagealjunctioncancerfollowingsurgicaltherapy AT aurelottlakan impactofneoadjuvantflottreatmentofadvancedgastricandgastroesophagealjunctioncancerfollowingsurgicaltherapy AT tibornyari impactofneoadjuvantflottreatmentofadvancedgastricandgastroesophagealjunctioncancerfollowingsurgicaltherapy AT zoltanszepes impactofneoadjuvantflottreatmentofadvancedgastricandgastroesophagealjunctioncancerfollowingsurgicaltherapy AT gabriellauhercsak impactofneoadjuvantflottreatmentofadvancedgastricandgastroesophagealjunctioncancerfollowingsurgicaltherapy AT anikomaraz impactofneoadjuvantflottreatmentofadvancedgastricandgastroesophagealjunctioncancerfollowingsurgicaltherapy AT laszlotorday impactofneoadjuvantflottreatmentofadvancedgastricandgastroesophagealjunctioncancerfollowingsurgicaltherapy AT laszlotiszlavicz impactofneoadjuvantflottreatmentofadvancedgastricandgastroesophagealjunctioncancerfollowingsurgicaltherapy AT juditolah impactofneoadjuvantflottreatmentofadvancedgastricandgastroesophagealjunctioncancerfollowingsurgicaltherapy AT gyorgylazar impactofneoadjuvantflottreatmentofadvancedgastricandgastroesophagealjunctioncancerfollowingsurgicaltherapy |